“Efforts have been made to address the limited use of MAT in drug courts. In 2015, the Bureau of Justice Assistance (BJA) began requiring drug courts receiving federal funding to attest in writing that they would not deny eligible candidates access to the program because of their use of an FDA-approved medication for addiction treatment, nor would participants be required to taper off such medications as a condition of graduating from the program. In 2016, the National Drug Court Institute endorsed MAT as a best practice for treatment of opioid use disorder.
Still, adoption has been slow. Below are three well-known barriers to broader availability of MAT for drug court participants, and ways they can be overcome.”
- Barrier #1: Access to MAT for Drug Court Participants
- Barrier #2: Concerns About Diversion
- Barrier #3: Negative Attitudes and Strict Rules
Source: ireta.org – May 9, 2017